Codexis, Inc. (CDXS)
NASDAQ: CDXS · Real-Time Price · USD
2.440
+0.050 (2.09%)
Jun 30, 2025, 4:00 PM - Market closed
Company Description
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.
It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Codexis, Inc.
| Country | United States |
| Founded | 2002 |
| IPO Date | Apr 22, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 188 |
| CEO | Stephen Dilly |
Contact Details
Address: 200 Penobscot Drive Redwood City, California 94063 United States | |
| Phone | 650 421 8100 |
| Website | codexis.com |
Stock Details
| Ticker Symbol | CDXS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001200375 |
| CUSIP Number | 192005106 |
| ISIN Number | US1920051067 |
| Employer ID | 71-0872999 |
| SIC Code | 2860 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stephen George Dilly MBBS, Ph.D. | President, Chief Executive Officer and Chairman |
| Georgia L. Erbez | Chief Financial Officer |
| Kevin Norrett M.B.A., M.S. | Chief Operating Officer |
| Dr. Alison Moore Ph.D. | Chief Technology Officer and Executive Vice President |
| Carrie McKim | Director of Investor Relations |
| Karen Frechou-Armijo | Senior Vice President and Head of Human Resources |
| Dr. Stefan Lutz Ph.D. | Senior Vice President of Research |
| John Schiffhauer | Senior Vice President of Intellectual Property |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 11, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| Apr 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 24, 2025 | SCHEDULE 13G/A | Filing |
| Apr 9, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |